Certain glucose-lowering meds associated with lower risk for COPD exacerbations
For patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disorder (COPD), sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs ...
FDA gives compounders short reprieve as Novo Nordisk GLP-1 supply normalizes
Novo Nordisk's (NVO) weight loss therapy Wegovy/Ozempic come out of shortage, but the FDA won't crack down on compounders ...
Healio1d
Top in women's health: GLP-1 use before pregnancy; developments in male contraception
A retrospective study demonstrated that GLP-1 receptor agonist use before pregnancy corresponded with lower risks for ...
gastroenterologyadvisor1d
Many With Overweight, Obesity Discontinue GLP-1 Receptor Agonists Within One Year
Many patients with overweight or obesity discontinue glucagon-like peptide-1 receptor agonist therapy within one year.
Why Novo Nordisk Is A Strong Buy Despite Market Concerns
Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...
Hosted on MSN1d
GLP-1RAs and opioid use disorder: a new frontier in addiction treatment
Glucagon-like peptide receptor agonists (GLP-1RAs) like Novo Nordisk’s semaglutide (Ozempic, Wegovy) and Eli Lilly’s ...
Medscape2d
GLP-1s and Nutrition: A Paradigm Shift Toward Quality and Sustainable Health
GLP-1s and nutrition: quality over restriction! Dr Almandoz shares how shifting from restrictive diets to evidence-based, ...
FierceBiotech2d
Ascletis' swift surge into obesity continues with competitive oral GLP-1 data
Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...